Astellas Pharma Inc.
Astellas Pharma Inc. (ALPMF) Stock Overview
Explore Astellas Pharma Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
18.7B
P/E Ratio
55.35
EPS (TTM)
$0.19
ROE
0.03%
ALPMF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Astellas Pharma Inc. (ALPMF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 65.06, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $7.89.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 55.35 and a market capitalization of 18.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.